Bolstered by a successful diversification strategy, Creative Life Science (啟新生技) reported record 2025 revenue of NT$1.097 billion (+27.5% YoY). The company has maintained a growth rate above 25% for two consecutive years.

Growth Drivers & 2026 Outlook:

• Regenerative Medicine: A new PIC/S GMP production base in the Hsinchu Biomedical Science Park is set to commence operations in Q1 2026. It will focus on cell culture media, critical reagents, and quality testing services.
• International Expansion: Creative Life Science is leveraging a strategic partnership with ESCO to penetrate the Southeast Asian market.
• Core Business: Stability in the CMP (Microbial Reagents) line and the integration of internal laboratory resources have increased customer stickiness in the food, biotech, and pharmaceutical sectors.

Resource: 啟新生技今年營運動能 高歌